APASL clinical practice guidelines on the management of acute kidney injury in acute-on-chronic liver failure.
ACLF
AKI
Portal hypertension
Journal
Hepatology international
ISSN: 1936-0541
Titre abrégé: Hepatol Int
Pays: United States
ID NLM: 101304009
Informations de publication
Date de publication:
05 Apr 2024
05 Apr 2024
Historique:
received:
30
11
2023
accepted:
20
01
2024
medline:
5
4
2024
pubmed:
5
4
2024
entrez:
5
4
2024
Statut:
aheadofprint
Résumé
Acute-on-chronic liver failure (ACLF) is a syndrome that is characterized by the rapid development of organ failures predisposing these patients to a high risk of short-term early death. The main causes of organ failure in these patients are bacterial infections and systemic inflammation, both of which can be severe. For the majority of these patients, a prompt liver transplant is still the only effective course of treatment. Kidneys are one of the most frequent extrahepatic organs that are affected in patients with ACLF, since acute kidney injury (AKI) is reported in 22.8-34% of patients with ACLF. Approach and management of kidney injury could improve overall outcomes in these patients. Importantly, patients with ACLF more frequently have stage 3 AKI with a low rate of response to the current treatment modalities. The objective of the present position paper is to critically review and analyze the published data on AKI in ACLF, evolve a consensus, and provide recommendations for early diagnosis, pathophysiology, prevention, and management of AKI in patients with ACLF. In the absence of direct evidence, we propose expert opinions for guidance in managing AKI in this very challenging group of patients and focus on areas of future research. This consensus will be of major importance to all hepatologists, liver transplant surgeons, and intensivists across the globe.
Identifiants
pubmed: 38578541
doi: 10.1007/s12072-024-10650-0
pii: 10.1007/s12072-024-10650-0
doi:
Types de publication
Editorial
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. Asian Pacific Association for the Study of the Liver.
Références
Sarin SK, Chandan K, Zaigham A, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL). Hepatol Int. 2014;8:453–471
pubmed: 26202751
doi: 10.1007/s12072-014-9580-2
Sarin SK, Kumar A, Almeida JA, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL). Hepatol Int. 2009;3(269):282
Sarin SK, Choudhury A, Sharma MK, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update [published correction appears in Hepatol Int. 2019 Nov, 13(6), pp. 826–828]. Hepatol Int. 2019;13:353–390
pubmed: 31172417
doi: 10.1007/s12072-019-09946-3
Piano S, Tonon M, Vettore E, et al. Incidence, predictors and outcomes of acute-on-chronic liver failure in outpatients with cirrhosis. J Hepatol. 2017;67(6):1177–1184
pubmed: 28733221
doi: 10.1016/j.jhep.2017.07.008
Wu T, Li J, Shao L, et al. Development of diagnostic criteria and a prognostic score for hepatitis B virus-related acute-on-chronic liver failure. Gut. 2018;67(12):2181–2191. https://doi.org/10.1136/gutjnl-2017-314641
doi: 10.1136/gutjnl-2017-314641
pubmed: 28928275
European Association for the Study of the Liver. EASL Clinical Practice Guidelines on acute-on-chronic liver failure. J Hepatol. 2023;79:461–491
doi: 10.1016/j.jhep.2023.04.021
Trebicka J, Fernandez J, Papp M, PREDICT STUDY group of the EASL-CLIF CONSORTIUM, et al. PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis. J Hepatol. 2021;74:1097–1108
pubmed: 33227350
doi: 10.1016/j.jhep.2020.11.019
Jalan R, Yurdaydin C, Bajaj JS, et al. Toward an improved definition of acute-on-chronic liver failure. Gastroenterology. 2014;147:4–10
pubmed: 24853409
doi: 10.1053/j.gastro.2014.05.005
Devarbhavi H, Choudhury AK, Sharma MK, et al. Drug-induced acute-on-chronic liver failure in Asian patients. Am J Gastroenterol. 2019;114:929–937
pubmed: 31021832
doi: 10.14309/ajg.0000000000000201
Maiwall R, Sarin SK, Moreau R. Acute kidney injury in acute on chronic liver failure. Hepatol Int. 2016;10:245–257
pubmed: 26471272
doi: 10.1007/s12072-015-9652-y
Maiwall R, Kumar S, Chandel SS, et al. AKI in patients with acute on chronic liver failure is different from acute decompensation of cirrhosis. Hepatol Int. 2015;9:627–639
pubmed: 26329121
doi: 10.1007/s12072-015-9653-x
Maiwall R, Sarin SK, Kumar S, et al. Development of predisposition, injury, response, organ failure model for predicting acute kidney injury in acute on chronic liver failure. Liver Int. 2017;37:1497–1507
pubmed: 28393476
doi: 10.1111/liv.13443
Maiwall R, Rastogi A, Pasupuleti SSR, et al. Natural history, spectrum and outcome of stage 3 AKI in patients with acute-on-chronic liver failure. Liver Int. 2022;42:2800–2814
pubmed: 36017749
doi: 10.1111/liv.15413
Angeli P, Garcia-Tsao G, Nadim MK, et al. News in pathophysiology, definition and classification of hepatorenal syndrome: a step beyond the International Club of Ascites (ICA) consensus document. J Hepatol. 2019;7:811–822
doi: 10.1016/j.jhep.2019.07.002
Amathieu R, Al-Khafaji A, Sileanu FEF, et al. Significance of oliguria in critically ill patients with chronic liver disease. Hepatology. 2017;66:1592–1600
pubmed: 28586126
doi: 10.1002/hep.29303
Bianchi NA, Stavart LL, Altarelli M, et al. Association of oliguria with acute kidney injury diagnosis, severity assessment, and mortality among patients with critical illness. JAMA Netw Open. 2021;1(4): e2133094
doi: 10.1001/jamanetworkopen.2021.33094
Maiwall R, Pasupuleti SSR, Chandel SS, et al. Co-orchestration of acute kidney injury and non-kidney organ failures in critically ill patients with cirrhosis. Liver Int. 2021;41:1358–1369
pubmed: 33534915
doi: 10.1111/liv.14809
Chawla LS, Bellomo R, Bihorac A, et al. Acute Disease Quality Initiative Workgroup 16. Acute kidney disease and renal recovery: consensus report of the Acute Disease Quality Initiative (ADQI) 16 Workgroup. Nat Rev Nephrol. 2017;13:241–257
pubmed: 28239173
doi: 10.1038/nrneph.2017.2
Maiwall R, Pasupuleti SSR, Hidam AK, et al. Non-resolution of acute kidney injury in the first week portends the development of chronic kidney disease in critically ill patients with cirrhosis. Aliment Pharmacol Ther. 2023. https://doi.org/10.1111/apt.17639
doi: 10.1111/apt.17639
pubmed: 37455381
Choudhury A, Kumar M, Sharma BC, APASL ACLF working party, et al. Systemic inflammatory response syndrome in acute-on-chronic liver failure: relevance of ‘golden window’: a prospective study. J Gastroenterol Hepatol. 2017;32:1989–1997
pubmed: 28374414
doi: 10.1111/jgh.13799
Clària J, Stauber RE, Coenraad MJ, CANONIC Study Investigators of the EASL-CLIF Consortium and the European Foundation for the Study of Chronic Liver Failure (EF-CLIF), et al. Systemic inflammation in decompensated cirrhosis: characterization and role in acute-on-chronic liver failure. Hepatology. 2016;64:1249–1264
pubmed: 27483394
doi: 10.1002/hep.28740
Arroyo V, Angeli P, Moreau R, Investigators from the EASL-CLIF Consortium, Grifols Chair and European Foundation for the Study of Chronic Liver Failure (EF-Clif), et al. The systemic inflammation hypothesis: Towards a new paradigm of acute decompensation and multiorgan failure in cirrhosis. J Hepatol. 2021;74:670–685
pubmed: 33301825
doi: 10.1016/j.jhep.2020.11.048
Moreau R, Clària J, Aguilar F, CANONIC Study Investigators of the EASL Clif Consortium; Grifols Chair; European Foundation for the Study of Chronic Liver Failure (EF Clif), et al. Blood metabolomics uncovers inflammation-associated mitochondrial dysfunction as a potential mechanism underlying ACLF. J Hepatol. 2020;72:688–701
pubmed: 31778751
doi: 10.1016/j.jhep.2019.11.009
Zaccherini G, Aguilar F, Caraceni P, et al. Assessing the role of amino acids in systemic inflammation and organ failure in patients with ACLF. J Hepatol. 2021;74:1117–1131
pubmed: 33276029
doi: 10.1016/j.jhep.2020.11.035
Clària J, Moreau R, Fenaille F, CANONIC Study Investigators of the EASL Clif Consortium, Grifols Chair and the European Foundation for the Study of Chronic Liver Failure (EF Clif), et al. Orchestration of tryptophan-kynurenine pathway, acute decompensation, and acute-on-chronic liver failure in cirrhosis. Hepatology. 2019;69:1686–1701
pubmed: 30521097
doi: 10.1002/hep.30363
van Slambrouck CM, Salem F, Meehan SM, et al. Bile cast nephropathy is a common pathologic finding for kidney injury associated with severe liver dysfunction. Kidney Int. 2013;84:192–197
pubmed: 23486516
doi: 10.1038/ki.2013.78
Fickert P, Rosenkranz AR. Cholemic nephropathy reloaded. Semin Liver Dis. 2020;40:91–100
pubmed: 31627236
doi: 10.1055/s-0039-1698826
Hofmann AF, Hagey LR. Bile acids: chemistry, pathochemistry, biology, pathobiology, and therapeutics. Cell Mol Life Sci. 2008;65:2461–2483
pubmed: 18488143
doi: 10.1007/s00018-008-7568-6
Lee J, Azzaroli F, Wang L, et al. Adaptive regulation of bile salt transporters in kidney and liver in obstructive cholestasis in the rat. Gastroenterology. 2001;121:1473–1484
pubmed: 11729126
doi: 10.1053/gast.2001.29608
Krones E, Eller K, Pollheimer MJ, et al. NorUrsodeoxycholic acid ameliorates cholemic nephropathy in bile duct ligated mice. J Hepatol. 2017;67:110–119
pubmed: 28242240
doi: 10.1016/j.jhep.2017.02.019
Bräsen JH, Mederacke YS, Schmitz J, et al. Cholemic nephropathy causes acute kidney injury and is accompanied by loss of aquaporin 2 in collecting ducts. Hepatology. 2019;69:2107–2119
pubmed: 30633816
doi: 10.1002/hep.30499
Nayak SL, Kumar M, Bihari C, et al. Bile cast nephropathy in patients with acute kidney injury due to hepatorenal syndrome: a post-mortem kidney biopsy study. J Clin Transl Hepatol. 2017;28(5):92–100
Kuwabara S, Goggins E, Okusa MD. The pathophysiology of sepsis-associated AKI. Clin J Am Soc Nephrol. 2022;17(7):1050–1069. https://doi.org/10.2215/CJN.00850122
doi: 10.2215/CJN.00850122
pubmed: 35764395
pmcid: 9269625
Maiwall R, Kumar G, Bharadwaj A, et al. AKI persistence at 48 h predicts mortality in patients with acute on chronic liver failure. Hepatol Int. 2017;11(6):529–539. https://doi.org/10.1007/s12072-017-9822-1
doi: 10.1007/s12072-017-9822-1
pubmed: 28983839
Chen YY, Chen DQ, Chen L, et al. Microbiome-metabolome reveals the contribution of gut-kidney axis on kidney disease. J Transl Med. 2019;17(1):5. https://doi.org/10.1186/s12967-018-1756-4 . (Published 2019 Jan 3)
doi: 10.1186/s12967-018-1756-4
pubmed: 30602367
pmcid: 6317198
Qin N, Yang F, Li A, et al. Alterations of the human gut microbiome in liver cirrhosis. Nature. 2014;513(7516):59–64. https://doi.org/10.1038/nature13568
doi: 10.1038/nature13568
pubmed: 25079328
Yang J, Kim CJ, Go YS, et al. Intestinal microbiota control acute kidney injury severity by immune modulation. Kidney Int. 2020;98(4):932–946. https://doi.org/10.1016/j.kint.2020.04.048
doi: 10.1016/j.kint.2020.04.048
pubmed: 32470493
Chawla LS, Bellomo R, Bihorac A, et al. Acute kidney disease and renal recovery: consensus report of the Acute Disease Quality Initiative (ADQI) 16 Workgroup. Nat Rev Nephrol. 2017;13:241–257
pubmed: 28239173
doi: 10.1038/nrneph.2017.2
Patidar KR, Naved MA, Grama A, et al. Acute kidney disease is common and associated with poor outcomes in patients with cirrhosis and acute kidney injury. J Hepatol. 2022;77:108–115
pubmed: 35217065
doi: 10.1016/j.jhep.2022.02.009
Tonon M, Rosi S, Gambino CG, et al. Natural history of acute kidney disease in patients with cirrhosis. J Hepatol. 2021;74:578–583
pubmed: 32918956
doi: 10.1016/j.jhep.2020.08.037
Maiwall R, Kumar A, Bhardwaj A, et al. Cystatin C predicts acute kidney injury and mortality in cirrhotics: a prospective cohort study. Liver Int. 2018;38(4):654–664
pubmed: 28941301
doi: 10.1111/liv.13600
Maiwall R, Pasupuleti SSR, Bihari C, et al. Incidence, risk factors, and outcomes of transition of acute kidney injury to chronic kidney disease in cirrhosis: a prospective cohort study. Hepatology. 2020;71:1009–1022
pubmed: 31313333
doi: 10.1002/hep.30859
Bassegoda O, Huelin P, Ariza X, et al. Development of chronic kidney disease after acute kidney injury in patients with cirrhosis is common and impairs clinical outcomes. J Hepatol. 2020;72:1132–1139
pubmed: 31953138
doi: 10.1016/j.jhep.2019.12.020
He L, Wei Q, Liu J, et al. AKI on CKD: heightened injury, suppressed repair, and the underlying mechanisms. Kidney Int. 2017;92:1071–1083
pubmed: 28890325
pmcid: 5683166
doi: 10.1016/j.kint.2017.06.030
Yazawa M, Maliakkal B, Nair S, et al. Longitudinal renal function in liver transplant recipients with acute-on-chronic liver failure. Clin Transl Gastroenterol. 2020;11: e00185
pubmed: 32568475
pmcid: 7339195
doi: 10.14309/ctg.0000000000000185
Morales-Alvarez MC. Nephrotoxicity of antimicrobials and antibiotics. Adv Chronic Kidney Dis. 2020;27:31–37
pubmed: 32146999
doi: 10.1053/j.ackd.2019.08.001
Patschan D, Patschan S, Buschmann I, et al. Loop diuretics in acute kidney injury prevention, therapy, and risk stratification. Kidney Blood Press Res. 2019;44:457–464
pubmed: 31362295
doi: 10.1159/000501315
Navis G, Faber HJ, de Zeeuw D, et al. ACE inhibitors and the kidney. A risk-benefit assessment. Drug Saf. 1996;15:200–211
pubmed: 8879974
doi: 10.2165/00002018-199615030-00005
Guevara M, Fernández-Esparrach G, Alessandria C, et al. Effects of contrast media on renal function in patients with cirrhosis: a prospective study. Hepatology. 2004;40:646–651
pubmed: 15349903
doi: 10.1002/hep.20373
Campion D, Ponzo P, Risso A, et al. A prospective, multicenter, three-cohort study evaluating contrast-induced acute kidney injury (CI-AKI) in patients with cirrhosis [published online ahead of print, 2023 Oct 19]. J Hepatol. 2023;S0168-8278(23)05176–0.
Zang H, Liu F, Liu H, et al. Incidence, risk factors and outcomes of acute kidney injury (AKI) in patients with acute-on-chronic liver failure (ACLF) of underlying cirrhosis. Hepatol Int. 2016;10:807–818
pubmed: 27485174
doi: 10.1007/s12072-016-9756-z
Arora V, Vijayaraghavan R, Maiwall R, et al. Paracentesis-induced circulatory dysfunction with modest-volume paracentesis is partly ameliorated by albumin infusion in acute-on-chronic liver failure. Hepatology. 2020;72:1043–1055
pubmed: 31849085
doi: 10.1002/hep.31071
Palsson R, Waikar SS. Renal functional reserve revisited. Adv Chronic Kidney Dis. 2018;25(3):e1–e8
pubmed: 29793670
doi: 10.1053/j.ackd.2018.03.001
Hsu WF, Yu SH, Lin JT, et al. Renal effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with liver cirrhosis: a nationwide cohort study. Gastroenterol Res Pract. 2019;10(2019):1743290
Tergast TL, Griemsmann M, Wedemeyer H, Cornberg M, Maasoumy B. Effects of renin–angiotensin inhibitors on renal function and the clinical course in patients with decompensated cirrhosis. Sci Rep. 2023;13(1):17486
pubmed: 37838780
pmcid: 10576780
doi: 10.1038/s41598-023-44299-w
Sersté T, Njimi H, Degré D, et al. The use of beta-blockers is associated with the occurrence of acute kidney injury in severe alcoholic hepatitis. Liver Int. 2015;35(8):1974–1982
pubmed: 25611961
doi: 10.1111/liv.12786
Clària J, Kent JD, López-Parra M, et al. Effects of celecoxib and naproxen on renal function in nonazotemic patients with cirrhosis and ascites. Hepatology. 2005;41(3):579–587
pubmed: 15723448
doi: 10.1002/hep.20595
Elia C, Graupera I, Barreto R, et al. Severe acute kidney injury associated with non-steroidal anti-inflammatory drugs in cirrhosis: a case-control study. J Hepatol. 2015;63(3):593–600
pubmed: 25872166
doi: 10.1016/j.jhep.2015.04.004
Randjelovic P, Veljkovic S, Stojiljkovic N, Sokolovic D, Ilic I. Gentamicin nephrotoxicity in animals: current knowledge and future perspectives. EXCLI J. 2017;24(16):388–399. https://doi.org/10.17179/excli2017-165 . (PMID: 28507482; PMCID: PMC5427480)
doi: 10.17179/excli2017-165
Vural A, Koçyiğit İ, Şan F, et al. Long-term protective effect of N-acetylcysteine against amikacin-induced ototoxicity in end-stage renal disease: a randomized trial. Perit Dial Int. 2018;38(1):57–62
pubmed: 29097487
doi: 10.3747/pdi.2017.00133
Kan W-C, Chen Y-C, Wu V-C, Shiao C-C. Vancomycin-associated acute kidney injury: a narrative review from pathophysiology to clinical application. Int J Mol Sci. 2022;23(4):2052
pubmed: 35216167
pmcid: 8877514
doi: 10.3390/ijms23042052
Velez JCQ, Obadan NO, Kaushal A, et al. Vancomycin-associated acute kidney injury with a steep rise in serum creatinine. Nephron. 2018;139:131–142
pubmed: 29705806
doi: 10.1159/000487149
Ordooei Javan A, Shokouhi S, Sahraei Z. A review on colistin nephrotoxicity. Eur J Clin Pharmacol. 2015;71(7):801–810. https://doi.org/10.1007/s00228-015-1865-4 . (Epub 2015 May 27 PMID: 26008213)
doi: 10.1007/s00228-015-1865-4
pubmed: 26008213
Shields RK, Anand R, Clarke LG, et al. Defining the incidence and risk factors of colistin-induced acute kidney injury by KDIGO criteria. PLoS ONE. 2017;12(3): e0173286. https://doi.org/10.1371/journal.pone.0173286 . (PMID: 28267779; PMCID: PMC5340380)
doi: 10.1371/journal.pone.0173286
pubmed: 28267779
pmcid: 5340380
Safdar A, Ma J, Saliba F, et al. Drug-induced nephrotoxicity caused by amphotericin B lipid complex and liposomal amphotericin B: a review and meta-analysis. Medicine (Baltimore). 2010;89(4):236–244
pubmed: 20616663
doi: 10.1097/MD.0b013e3181e9441b
Wan ZH, Wang JJ, You SL, et al. Cystatin C is a biomarker for predicting acute kidney injury in patients with acute-on-chronic liver failure. World J Gastroenterol. 2013;28(19):9432–9438
doi: 10.3748/wjg.v19.i48.9432
Mauro E, Crespo G, Martinez-Garmendia A, et al. Cystatin C and sarcopenia predict acute on chronic liver failure development and mortality in patients on the liver transplant waiting list. Transplantation. 2020;104(7):e188–e198
pubmed: 32150034
doi: 10.1097/TP.0000000000003222
Jha P, Jha AK, Dayal VM, et al. Baseline serum cystatin C as a marker of acute kidney injury in patients with acute-on-chronic liver failure. Indian J Gastroenterol. 2021;40:563–571
pubmed: 34981441
doi: 10.1007/s12664-021-01201-8
Saha R, Sharma S, Mondal A, et al. Evaluation of serum kidney injury markers FABP1, NGAL, cystatin C and the inflammatory cytokine IL-18 in the detection of acute-on-chronic liver failure (ACLF) associated acute kidney injury (AKI). Res Sq. 2022. https://doi.org/10.21203/rs.3.rs-2186737/v1
doi: 10.21203/rs.3.rs-2186737/v1
Markwardt D, Holdt L, Steib C, et al. Plasma cystatin C is a predictor of renal dysfunction, acute-on-chronic liver failure, and mortality in patients with acutely decompensated liver cirrhosis. Hepatology. 2017;66:1232–1241
pubmed: 28545169
doi: 10.1002/hep.29290
Lu J, Lin L, Ye C, et al. Serum NGAL is superior to cystatin c in predicting the prognosis of acute-on-chronic liver failure. Ann Hepatol. 2019;18(1):155–164
pubmed: 31113585
doi: 10.5604/01.3001.0012.7907
Jiang QQ, Han MF, Ma K, et al. Acute kidney injury in acute-on-chronic liver failure is different from in decompensated cirrhosis. World J Gastroenterol. 2018;24(21):2300–2310
pubmed: 29881239
pmcid: 5989244
doi: 10.3748/wjg.v24.i21.2300
Barreto R, Elia C, Solà E, et al. Urinary neutrophil gelatinase-associated lipocalin predicts kidney outcome and death in patients with cirrhosis and bacterial infections. J Hepatol. 2014;61(1):35–42. https://doi.org/10.1016/j.jhep.2014.02.023 . (Epub 2014 Mar 5 PMID: 24613364)
doi: 10.1016/j.jhep.2014.02.023
pubmed: 24613364
Kim TH, Seo YS, Kang SH, Korean Study Group of Portal Hypertension, et al. Prognosis predictability of serum and urine renal markers in patients with decompensated cirrhosis: a multicentre prospective study. Liver Int. 2020;40(12):3083–3092. https://doi.org/10.1111/liv.14631 . (PMID: 32750739)
doi: 10.1111/liv.14631
pubmed: 32750739
Huelin P, Solà E, Elia C, et al. Neutrophil gelatinase-associated lipocalin for assessment of acute kidney injury in cirrhosis: a prospective study. Hepatology. 2019;70(1):319–333. https://doi.org/10.1002/hep.30592 . (Epub 2019 Apr 25 PMID: 30810244)
doi: 10.1002/hep.30592
pubmed: 30810244
Ariza X, Graupera I, Coll M, CANONIC Investigators, EASL CLIF Consortium, et al. Neutrophil gelatinase-associated lipocalin is a biomarker of acute-on-chronic liver failure and prognosis in cirrhosis. J Hepatol. 2016;65:57–65
pubmed: 26988732
doi: 10.1016/j.jhep.2016.03.002
Ariza X, Solà E, Elia C, et al. Analysis of a urinary biomarker panel for clinical outcomes assessment in cirrhosis. PLoS ONE. 2015;10(6): e0128145. https://doi.org/10.1371/journal.pone.0128145 . (PMID: 26042740; PMCID: PMC4456079)
doi: 10.1371/journal.pone.0128145
pubmed: 26042740
pmcid: 4456079
Gambino C, Piano S, Stenico M, et al. Diagnostic and prognostic performance of urinary neutrophil gelatinase-associated lipocalin in patients with cirrhosis and acute kidney injury. Hepatology. 2023;1(77):1630–1638. https://doi.org/10.14309/ctg.0000000000000359 . (PMID: 33979307; PMCID: PMC8116001)
doi: 10.14309/ctg.0000000000000359
Tsai MH, Chen YC, Yang CW, et al. Acute renal failure in cirrhotic patients with severe sepsis: value of urinary interleukin-18. J Gastroenterol Hepatol. 2013;28(1):135–141. https://doi.org/10.1111/j.1440-1746.2012.07288.x . (PMID: 23034155)
doi: 10.1111/j.1440-1746.2012.07288.x
pubmed: 23034155
Belcher JM, Sanyal AJ, Peixoto AJ, TRIBE-AKI Consortium, et al. Kidney biomarkers and differential diagnosis of patients with cirrhosis and acute kidney injury. Hepatology. 2014;60(2):622–632. https://doi.org/10.1002/hep.26980 . (Epub 2014 Jun 26. PMID: 24375576; PMCID: PMC4065642)
doi: 10.1002/hep.26980
pubmed: 24375576
Eguchi A, Hasegawa H, Iwasa M, et al. Serum liver-type fatty acid-binding protein is a possible prognostic factor in human chronic liver diseases from chronic hepatitis to liver cirrhosis and hepatocellular carcinoma. Hepatol Commun. 2019;3(6):825–837. https://doi.org/10.1002/hep4.1350 . (PMID: 31168516; PMCID: PMC6545868)
doi: 10.1002/hep4.1350
pubmed: 31168516
pmcid: 6545868
Kulkarni AV, Sharma M, Kumar P, et al. Adipocyte fatty acid-binding protein as a predictor of outcome in alcohol-induced acute-on-chronic liver failure. J Clin Exp Hepatol. 2021;11(2):201–208. https://doi.org/10.1016/j.jceh.2020.07.010 . (Epub 2020 Jul 28. PMID: 33746445; PMCID: PMC7953014)
doi: 10.1016/j.jceh.2020.07.010
pubmed: 33746445
Zhang CC, Hoffelt DAA, Merle U. Urinary cell cycle arrest biomarker [TIMP-2]·[IGFBP7] in patients with hepatorenal syndrome. Biomarkers. 2019;24(7):692–699. https://doi.org/10.1080/1354750X.2019.1652347 . (Epub 2019 Aug 22 PMID: 31389249)
doi: 10.1080/1354750X.2019.1652347
pubmed: 31389249
Kerbert AJC, Gupta S, Alabsawy E, et al. Biomarkers of extracellular matrix formation are associated with acute-on-chronic liver failure. JHEP Rep. 2021;3: 100355. https://doi.org/10.1016/j.jhepr.2021.100355 . (Published 2021 Aug 27)
doi: 10.1016/j.jhepr.2021.100355
pubmed: 34805815
pmcid: 8581571
Lei L, Li LP, Zeng Z, et al. Value of urinary KIM-1 and NGAL combined with serum Cys C for predicting acute kidney injury secondary to decompensated cirrhosis. Sci Rep. 2018;8(1):7962
pubmed: 29784944
pmcid: 5962573
doi: 10.1038/s41598-018-26226-6
Levitsky J, Asrani SK, Abecassis M, et al. External validation of a pretransplant biomarker model (REVERSE) predictive of renal recovery after liver transplantation. Hepatology. 2019;70(4):1349–1359. https://doi.org/10.1002/hep.30667 . (Epub 2019 May 28 PMID: 31002431)
doi: 10.1002/hep.30667
pubmed: 31002431
Patidar KR, Xu C, Shamseddeen H, et al. Development and validation of a model to predict acute kidney injury in hospitalized patients with cirrhosis. Clin Transl Gastroenterol. 2019;10: e00075
pubmed: 31478958
pmcid: 6775340
doi: 10.14309/ctg.0000000000000075
Wang ML, Yin XJ, Li XL, et al. Retrospective analysis of the clinical efficacy of n-acetylcysteine in the treatment of hepatitis B virus related acute-on-chronic liver failure. Front Med (Lausanne). 2021;5(8): 724224
doi: 10.3389/fmed.2021.724224
Kulkarni AV, Anand L, Vyas AK, et al. Omega-3 fatty acid lipid emulsions are safe and effective in reducing endotoxemia and sepsis in acute-on-chronic liver failure: An open-label randomized controlled trial. J Gastroenterol Hepatol. 2021;36:1953–1961
pubmed: 33450081
doi: 10.1111/jgh.15400
Phillips M, Curtis H, Portmann B, et al. Antioxidants versus corticosteroids in the treatment of severe alcoholichepatitis–a randomised clinical trial. J Hepatol. 2006;44:784–790
pubmed: 16469404
doi: 10.1016/j.jhep.2005.11.039
Moreno C, Langlet P, Hittelet A, et al. Enteral nutrition with or without N-acetylcysteine in the treatment of severe acute alcoholichepatitis: a randomized multicenter controlled trial. J Hepatol. 2010;53:1117–1122
pubmed: 20801542
doi: 10.1016/j.jhep.2010.05.030
Nguyen-Khac E, Thevenot T, Piquet MA, AAH-NAC Study Group, et al. Glucocorticoids plus N-acetylcysteine in severe alcohol-related hepatitis. N Engl J Med. 2011;365:1781–1789
pubmed: 22070475
doi: 10.1056/NEJMoa1101214
Forrest E, Mellor J, Stanton L, et al. Steroids or pentoxifylline for alcoholichepatitis (STOPAH): study protocol for a randomised controlled trial. Trials. 2013;19(14):262. https://doi.org/10.1186/1745-6215-14-262
doi: 10.1186/1745-6215-14-262
Szabo G, Mitchell M, McClain CJ, et al. IL-1 receptor antagonist plus pentoxifylline and zinc for severe alcohol-associated hepatitis. Hepatology. 2022;76:1058–1068
pubmed: 35340032
doi: 10.1002/hep.32478
Singh V, Keisham A, Bhalla A, et al. Efficacy of granulocyte colony-stimulating factor and N-acetylcysteine therapies in patients with severe alcoholic hepatitis. Clin Gastroenterol Hepatol. 2018;16:1650-1656.e2
pubmed: 29391265
doi: 10.1016/j.cgh.2018.01.040
Lee WM, Hynan LS, Rossaro L, et al. Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure [published correction appears in Gastroenterology. 2013 Sep;145(3):695. Dosage error in article text]. Gastroenterology. 2009;137(3):856-864.e1
pubmed: 19524577
doi: 10.1053/j.gastro.2009.06.006
Walayat S, Shoaib H, Asghar M, Kim M, Dhillon S. Role of N-acetylcysteine in non-acetaminophen-related acute liver failure: an updated meta-analysis and systematic review. Ann Gastroenterol. 2021;34(2):235–240
pubmed: 33654365
pmcid: 7903568
Wang ML, Yin XJ, Li XL, et al. Retrospective analysis of the clinical efficacy of N-acetylcysteine in the treatment of hepatitis B virus related acute-on-chronic liver failure. Front Med (Lausanne). 2021;8: 724224 (Published 2021 Aug 5)
pubmed: 34422872
pmcid: 8375028
doi: 10.3389/fmed.2021.724224
Bai Z, Méndez-Sánchez N, Romeiro FG, et al. Use of albumin infusion for cirrhosis-related complications: An international position statement. JHEP Rep. 2023;5(8): 100785 (Published 2023 May 5)
pubmed: 37456673
pmcid: 10339261
doi: 10.1016/j.jhepr.2023.100785
Sort P, Navasa M, Arroyo V, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med. 1999;341(6):403–409
pubmed: 10432325
doi: 10.1056/NEJM199908053410603
European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol. 2010;53:397–417
doi: 10.1016/j.jhep.2010.05.004
Fernández J, Clària J, Amorós A, et al. Effects of albumin treatment on systemic and portal hemodynamics and systemic inflammation in patients with decompensated cirrhosis. Gastroenterology. 2019;157:149–162
pubmed: 30905652
doi: 10.1053/j.gastro.2019.03.021
Mookerjee RP, Stadlbauer V, Lidder S, et al. Neutrophil dysfunction in alcoholic hepatitis superimposed on cirrhosis is reversible and predicts the outcome. Hepatology. 2007;46(3):831–840
pubmed: 17680644
doi: 10.1002/hep.21737
Engelmann C, Herber A, Franke A, et al. Granulocyte-colony stimulating factor (G-CSF) to treat acute-on-chronic liver failure: a multicenter randomized trial (GRAFT study). J Hepatol. 2021;75:1346–1354
pubmed: 34364917
doi: 10.1016/j.jhep.2021.07.033
Engelmann C, Habtesion A, Hassan M, et al. Combination of G-CSF and a TLR4 inhibitor reduce inflammation and promote regeneration in a mouse model of ACLF. J Hepatol. 2022;77:1325–1338
pubmed: 35843375
doi: 10.1016/j.jhep.2022.07.006
Martin-Mateos R, González-Alonso R, Álvarez-Díaz N, et al. Granulocyte-colony stimulating factor in acute-on-chronic liver failure: systematic review and meta-analysis of randomized controlled trials. Gastroenterol Hepatol. 2023;46:350–359
pubmed: 36174797
doi: 10.1016/j.gastrohep.2022.09.007
Moreau R, Rautou PE. G-CSF therapy for severe alcohol-related hepatitis: targeting liver regeneration or neutrophil function? Am J Gastroenterol. 2014;109:1424–1426
pubmed: 25196873
doi: 10.1038/ajg.2014.250
Engelmann C, Martino VD, Kerbert AJC, et al. The current status of granulocyte-colony stimulating factor to treat acute-on-chronic liver failure. Semin Liver Dis. 2021;41:298–307
pubmed: 33992029
doi: 10.1055/s-0041-1723034
Duan XZ, Liu FF, Tong JJ, et al. Granulocyte-colony stimulating factor therapy improves survival in patients with hepatitis B virus-associated acute-on-chronic liver failure. World J Gastroenterol. 2013;21(19):1104–1110
doi: 10.3748/wjg.v19.i7.1104
Garg V, Garg H, Khan A, et al. Granulocyte colony-stimulating factor mobilizes CD34(+) cells and improves survival of patients with acute-on-chronic liver failure. Gastroenterology. 2012;142:505-512.e1
pubmed: 22119930
doi: 10.1053/j.gastro.2011.11.027
Altered frequencies of dendritic cells and IFN-gamma-secreting T cells with granulocyte colony-stimulating factor (G-CSF) therapy in acute-on- chronic liver failure. Liver Int. 2014 ;34:505–13.
Marot A, Singal AK, Moreno C, et al. A systematic review and meta-analysis of randomised controlled trials. JHEP Rep. 2020;18(2): 100139
doi: 10.1016/j.jhepr.2020.100139
Singh V, Sharma AK, Narasimhan RL, et al. Granulocyte colony-stimulating factor in severe alcoholichepatitis: a randomized pilot study. Am J Gastroenterol. 2014;109:1417–1423
pubmed: 24935272
doi: 10.1038/ajg.2014.154
Mookerjee RP, Pavesi M, Thomsen KL, CANONIC Study Investigators of the EASL-CLIF Consortium, et al. Treatment with non-selective beta blockers is associated with reduced severity of systemic inflammation and improved survival of patients with acute-on-chronic liver failure. J Hepatol. 2016;64:574–582
pubmed: 26519600
doi: 10.1016/j.jhep.2015.10.018
Kumar M, Kainth S, Choudhury A, et al. Treatment with carvedilol improves survival of patients with acute-on-chronic liver failure: a randomized controlled trial. Hepatol Int. 2019;13:800–813
pubmed: 31541422
doi: 10.1007/s12072-019-09986-9
Kulkarni AV, Tirumalle S, Premkumar M, et al. Primary norfloxacin prophylaxis for APASL-defined acute-on-chronic liver failure: a placebo-controlled double-blind randomized trial. Am J Gastroenterol. 2022;1(117):607–616
doi: 10.14309/ajg.0000000000001611
Ostermann M, Liu K, Kashani K. Fluid management in acute kidney injury. Chest. 2019;156:594–603. https://doi.org/10.1016/j.chest.2019.04.004 . (Epub 2019 Apr 16)
doi: 10.1016/j.chest.2019.04.004
pubmed: 31002784
Kellum JA, Romagnani P, Ashuntantang G, et al. Acute kidney injury. Nat Rev Dis Primers. 2021;15(7):52. https://doi.org/10.1038/s41572-021-00284-z
doi: 10.1038/s41572-021-00284-z
Singbartl K, Kellum JA. AKI in the ICU: definition, epidemiology, risk stratification, and outcomes. Kidney Int. 2012;81:819–825
pubmed: 21975865
doi: 10.1038/ki.2011.339
Chuang CL. Fluid management in acute kidney injury. Contrib Nephrol. 2016;187:84–93
pubmed: 26882226
doi: 10.1159/000442368
Malbrain MLNG, Van Regenmortel N, Saugel B, et al. Principles of fluid management and stewardship in septic shock: it is time to consider the four D’s and the four phases of fluid therapy. Ann Intensive Care. 2018;22(8):66
doi: 10.1186/s13613-018-0402-x
Hoste EA, Maitland K, Brudney CS, ADQI XII Investigators Group, et al. Four phases of intravenous fluid therapy: a conceptual model. Br J Anaesth. 2014;113:740–747
pubmed: 25204700
doi: 10.1093/bja/aeu300
Vaara ST, Ostermann M, Bitker L, REVERSE-AKI study team, et al. Restrictive fluid management versus usual care in acute kidney injury (REVERSE-AKI): a pilot randomized controlled feasibility trial. Intensive Care Med. 2021;47:665–673. https://doi.org/10.1007/s00134-021-06401-6
doi: 10.1007/s00134-021-06401-6
pubmed: 33961058
pmcid: 8195764
Grissom CK, Hirshberg EL, Dickerson JB, National Heart Lung and Blood Institute Acute Respiratory Distress Syndrome Clinical Trials Network, et al. Fluid management with a simplified conservative protocol for the acute respiratory distress syndrome*. Crit Care Med. 2015;43:288–295
pubmed: 25599463
pmcid: 4675623
doi: 10.1097/CCM.0000000000000715
Philips CA, Maiwall R, Sharma MK, et al. Comparison of 5% human albumin and normal saline for fluid resuscitation in sepsis induced hypotension among patients with cirrhosis (FRISC study): a randomized controlled trial. Hepatol Int. 2021;15:983–994
pubmed: 34036519
doi: 10.1007/s12072-021-10164-z
Finfer S, Bellomo R, Boyce N, SAFE Study Investigators, et al. A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med. 2004;350:2247–2256
pubmed: 15163774
doi: 10.1056/NEJMoa040232
Maiwall R, Kumar A, Pasupuleti SSR, et al. A randomized-controlled trial comparing 20% albumin to PlasmaLyte in patients with cirrhosis and sepsis-induced hypotension [ALPS trial]. J Hepatol. 2022;77:670–682
pubmed: 35460725
doi: 10.1016/j.jhep.2022.03.043
Sen A, Keener CM, Sileanu FE, et al. Chloride content of fluids used for large-volume resuscitation is associated with reduced survival. Crit Care Med. 2016;45:e146–e153
doi: 10.1097/CCM.0000000000002063
Van Haren F. Personalised fluid resuscitation in the ICU: still a fluid concept? Crit Care. 2017;21(suppl 3):313
pubmed: 29297387
pmcid: 5751583
doi: 10.1186/s13054-017-1909-5
Young P, Bailey M, Beasley R, et al. Effect of a buffered crystalloid solution vs saline on acute kidney injury among patients in the intensive care unit: the SPLIT randomized clinical trial. JAMA. 2015;314:1701–1710
pubmed: 26444692
doi: 10.1001/jama.2015.12334
Reddy SK, Bailey MJ, Beasley RW, et al. A protocol for the 0.9% saline versus Plasma-Lyte 148 for intensive care fluid therapy (SPLIT) study. Crit Care Resusc. 2014;16(4):274–279
pubmed: 25437221
Semler MW, Self WH, Wanderer JP, et al. Balanced crystalloids versus saline in critically ill adults. N Engl J Med. 2018;378(9):829–839. https://doi.org/10.1056/NEJMoa1711584
doi: 10.1056/NEJMoa1711584
pubmed: 29485925
pmcid: 5846085
Finfer S, Micallef S, Hammond N, PLUS Study Investigators and the Australian New Zealand Intensive Care Society Clinical Trials Group, et al. Balanced multielectrolyte solution versus saline in critically ill adults. N Engl J Med. 2022;386:815–826
pubmed: 35041780
doi: 10.1056/NEJMoa2114464
Beaubien-Souligny W, Trott T, Neyra JA. How to determine fluid management goals during continuous kidney replacement therapy in patients with AKI: focus on POCUS. Kidney360. 2022;3:1795–1806
pubmed: 36514727
pmcid: 9717662
doi: 10.34067/KID.0002822022
Caraceni P, Riggio O, Angeli P, ANSWER Study Investigators, et al. Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial. Lancet. 2018;391(10138):2417–2429. https://doi.org/10.1016/S0140-6736(18)30840-7 . (Epub 2018 Jun 1. Erratum in: Lancet. 2018 Aug 4;392(10145):386. PMID: 29861076)
doi: 10.1016/S0140-6736(18)30840-7
pubmed: 29861076
Goldstein SL. Fluid management in acute kidney injury. J Intensive Care Med. 2014;29:183–189
pubmed: 23753221
doi: 10.1177/0885066612465816
Nadeau-Fredette AC, Bouchard J. Fluid management and use of diuretics in acute kidney injury. Adv Chronic Kidney Dis. 2013;20:45–55
pubmed: 23265596
doi: 10.1053/j.ackd.2012.09.005
Zhou S, Zeng Z, Wei H, et al. Early combination of albumin with crystalloids administration might be beneficial for the survival of septic patients: a retrospective analysis from MIMIC-IV database. Ann Intensive Care. 2021;11:42
pubmed: 33689042
pmcid: 7947075
doi: 10.1186/s13613-021-00830-8
Barjaktarevic I, Toppen WE, Hu S, et al. Ultrasound assessment of the change in carotid corrected flow time in fluid responsiveness in undifferentiated shock. Crit Care Med. 2018;46:e1040–e1046. https://doi.org/10.1097/CCM.0000000000003356
doi: 10.1097/CCM.0000000000003356
pubmed: 30134304
pmcid: 6774608
Jalil B, Thompson P, Cavallazzi R, et al. Comparing changes in carotid flow time and stroke volume induced by passive leg raising. Am J Med Sci. 2018;355:168–173. https://doi.org/10.1016/j.amjms.2017.09.006
doi: 10.1016/j.amjms.2017.09.006
pubmed: 29406045
Slama M, Masson H, Teboul JL, et al. A new index of hypovolemia and fluid responsiveness. Am J Physiol Heart Circ Physiol. 2002;283:H1729–H1733. https://doi.org/10.1152/ajpheart.00308.2002
doi: 10.1152/ajpheart.00308.2002
pubmed: 12234829
KDIGO AKI Work Group. KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl. 2012;2:1–138
Hjortrup PB, Haase N, Bundgaard H, et al. Restricting volumes of resuscitation fluid in adults with septic shock after initial management: the CLASSIC randomised, parallel-group, multicentre feasibility trial. Intensive Care Med. 2016;42:1695–1705
pubmed: 27686349
doi: 10.1007/s00134-016-4500-7
China L, Freemantle N, Forrest E, et al. A randomized trial of albumin infusions in hospitalized patients with cirrhosis. N Engl J Med. 2021;4(384):808–817
doi: 10.1056/NEJMoa2022166
Premkumar M, Kajal K, Reddy KR, et al. Evaluation of terlipressin-related patient outcomes in hepatorenal syndrome-acute kidney injury using point-of-care echocardiography. Hepatology. 2023. https://doi.org/10.1097/HEP.0000000000000691 . (Published online November 17, 2023)
doi: 10.1097/HEP.0000000000000691
pubmed: 37976391
Wong F, Pappas SC, Curry MP, CONFIRM Study Investigators, et al. Terlipressin plus albumin for the treatment of type 1 hepatorenal syndrome. N Engl J Med. 2021;4(384):818–828
doi: 10.1056/NEJMoa2008290
Arora V, Maiwall R, Rajan V, et al. Terlipressin is superior to noradrenaline in the management of acute kidney injury in acute on chronic liver failure. Hepatology. 2020;71:600–610
pubmed: 30076614
doi: 10.1002/hep.30208
Jindal A, Bhadoria AS, Maiwall R, et al. Evaluation of acute kidney injury and its response to terlipressin in patients with acute-on-chronic liver failure. Liver Int. 2016;36:59–67
pubmed: 26081914
doi: 10.1111/liv.12895
Massicotte L, Perrault MA, Denault AY, et al. Effects of phlebotomy and phenylephrine infusion on portal venous pressure and systemic hemodynamics during liver transplantation. Transplantation. 2010;89:920–927
pubmed: 20216483
doi: 10.1097/TP.0b013e3181d7c40c
Moreau R, Barrière E, Tazi KA, et al. Terlipressin inhibits in vivo aortic iNOS expression induced by lipopolysaccharide in rats with biliary cirrhosis. Hepatology. 2002;36:1070–1078
pubmed: 12395316
doi: 10.1053/jhep.2002.36501
Piano S, Gambino C, Vettore E, et al. Response to terlipressin and albumin is associated with improved liver transplant outcomes in patients with hepatorenal syndrome. Hepatology. 2021;73:1909–1919
pubmed: 32870499
doi: 10.1002/hep.31529
Singh H, Jindal A, Sharma MK, et al. Early versus standard initiation of terlipressin for HRS-AKI In ACLF—a randomized controlled trial (eTerli study) abstracts. Hepatology. 2022. https://doi.org/10.1002/hep.32697
doi: 10.1002/hep.32697
pubmed: 35781890
Boyer TD, Sanyal AJ, Garcia-Tsao G, et al. Predictors of response to terlipressin plus albumin in hepatorenal syndrome (HRS) type 1: relationship of serum creatinine to hemodynamics. J Hepatol. 2011;55(2):315–321. https://doi.org/10.1016/j.jhep.2010.11.020
doi: 10.1016/j.jhep.2010.11.020
pubmed: 21167235
Nazar A, Pereira GH, Guevara M, et al. Predictors of response to therapy with terlipressin and albumin in patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology. 2010;51(1):219–226. https://doi.org/10.1002/hep.23283
doi: 10.1002/hep.23283
pubmed: 19877168
Velez JC, Nietert PJ. Therapeutic response to vasoconstrictors in hepatorenal syndrome parallels increase in mean arterial pressure: a pooled analysis of clinical trials. Am J Kidney Dis. 2011;58(6):928–938. https://doi.org/10.1053/j.ajkd.2011.07.017
doi: 10.1053/j.ajkd.2011.07.017
pubmed: 21962618
pmcid: 3251915
Zheng X, Lian Y, Wang P, et al. Mean arterial pressure drop is an independent risk factor of hepatorenal syndrome in patients with HBV-ACLF. Eur J Gastroenterol Hepatol. 2022;34(5):576–584. https://doi.org/10.1097/MEG.0000000000002314
doi: 10.1097/MEG.0000000000002314
pubmed: 35131999
pmcid: 9076250
Maiwall R, Rao Pasupuleti SS, Hidam AK, et al. A randomised-controlled trial (TARGET-C) of high vs low target mean arterial pressure in patients with cirrhosis and septic shock. J Hepatol. 2023;79:349–361
pubmed: 37088310
doi: 10.1016/j.jhep.2023.04.006
Cavallin M, Piano S, Romano A, et al. Terlipressin given by continuous intravenous infusion versus intravenous boluses in the treatment of hepatorenal syndrome: a randomized controlled study. Hepatology. 2016;63(3):983–992. https://doi.org/10.1002/hep.28396
doi: 10.1002/hep.28396
pubmed: 26659927
Singh V, Ghosh S, Singh B, et al. Noradrenaline vs terlipressin in the treatment of hepatorenal syndrome: a randomized study. J Hepatol. 2012;56(6):1293–1298. https://doi.org/10.1016/j.jhep.2012.01.012 . (Epub 2012 Feb 6. PMID: 22322237)
doi: 10.1016/j.jhep.2012.01.012
pubmed: 22322237
Boyer TD, Sanyal AJ, Wong F, REVERSE Study Investigators, et al. Terlipressin plus albumin is more effective than albumin alone in improving renal function in patients with cirrhosis and hepatorenal syndrome type 1. Gastroenterology. 2016;150(7):1579-1589.e2. https://doi.org/10.1053/j.gastro.2016.02.026 . (Epub 2016 Feb 16 PMID: 26896734)
doi: 10.1053/j.gastro.2016.02.026
pubmed: 26896734
Sharma P, Kumar A, Shrama BC, Sarin SK. An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response. Am J Gastroenterol. 2008;103(7):1689–1697. https://doi.org/10.1111/j.1572-0241.2008.01828.x . (Epub 2008 Jun 28 PMID: 18557715)
doi: 10.1111/j.1572-0241.2008.01828.x
pubmed: 18557715
Cavallin M, Kamath PS, Merli M, Italian Association for the Study of the Liver Study Group on Hepatorenal Syndrome, et al. Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: a randomized trial. Hepatology. 2015;62(2):567–574. https://doi.org/10.1002/hep.27709 . (Epub 2015 Feb 13 PMID: 25644760)
doi: 10.1002/hep.27709
pubmed: 25644760
Solà E, Solé C, Simón-Talero M, et al. Midodrine and albumin for prevention of complications in patients with cirrhosis awaiting liver transplantation. A randomized placebo-controlled trial. J Hepatol. 2018;69(6):1250–1259. https://doi.org/10.1016/j.jhep.2018.08.006 . (Epub 2018 Aug 21 PMID: 30138685)
doi: 10.1016/j.jhep.2018.08.006
pubmed: 30138685
Solanki P, Chawla A, Garg R, et al. Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebo-controlled clinical trial. J Gastroenterol Hepatol. 2003;18(2):152–156. https://doi.org/10.1046/j.1440-1746.2003.02934.x . (PMID: 12542598)
doi: 10.1046/j.1440-1746.2003.02934.x
pubmed: 12542598
Alessandria C, Ottobrelli A, Debernardi-Venon W, et al. Noradrenalin vs terlipressin in patients with hepatorenal syndrome: a prospective, randomized, unblinded, pilot study. J Hepatol. 2007;47(4):499–505. https://doi.org/10.1016/j.jhep.2007.04.010 . (Epub 2007 May 24 PMID: 17560680)
doi: 10.1016/j.jhep.2007.04.010
pubmed: 17560680
Sanyal AJ, Boyer T, Garcia-Tsao G, Terlipressin Study Group, et al. A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology. 2008;134(5):1360–1368. https://doi.org/10.1053/j.gastro.2008.02.014
doi: 10.1053/j.gastro.2008.02.014
pubmed: 18471513
STARRT-AKI Investigators; Canadian Critical Care Trials Group; Australian and New Zealand Intensive Care Society Clinical Trials Group. Timing of initiation of renal-replacement therapy in acute kidney injury [published correction appears in N Engl J Med. 2020 Jul 15;:]. N Engl J Med. 2020;383(3):240–251. https://doi.org/10.1056/NEJMoa2000741
doi: 10.1056/NEJMoa2000741
Zarbock A, Kellum JA, Schmidt C, et al. Effect of early vs delayed initiation of renal replacement therapy on mortality in critically ill patients with acute kidney injury: the ELAIN randomized clinical trial. JAMA. 2016;24–31(315):2190–2199
doi: 10.1001/jama.2016.5828
Gaudry S, Hajage D, Schortgen F, et al. Initiation strategies for renal-replacement therapy in the intensive care unit. N Engl J Med. 2016;375:122–133
pubmed: 27181456
doi: 10.1056/NEJMoa1603017
Gaudry S, Hajage D, Schortgen F, et al. Timing of renal support and outcome of septic shock and acute respiratory distress syndrome. A post hoc analysis of the AKIKI randomized clinical trial. Am J Respir Crit Care Med. 2018;1(198):58–66
doi: 10.1164/rccm.201706-1255OC
Lin WT, Lai CC, Chang SP, Wang JJ. Effects of early dialysis on the outcomes of critically ill patients with acute kidney injury: a systematic review and meta-analysis of randomized controlled trials. Sci Rep. 2019;9(1):18283
pubmed: 31797991
pmcid: 6892880
doi: 10.1038/s41598-019-54777-9
Gaudry S, Hajage D, Martin-Lefevre L, et al. Comparison of two delayed strategies for renal replacement therapy initiation for severe acute kidney injury (AKIKI 2): a multicentre, open-label, randomised, controlled trial. Lancet. 2021;397(10281):1293–1300
pubmed: 33812488
doi: 10.1016/S0140-6736(21)00350-0
Maiwall R, Hidam A, Kadyan S, et al. Early versus late continuous renal replacement therapy in ACLF patients with septic shock and acute kidney injury. Hepatology. 2022;76(S1):S122. https://doi.org/10.1002/hep.32697
doi: 10.1002/hep.32697
Meersch M, Küllmar M, Schmidt C, et al. Long-term clinical outcomes after early initiation of rrt in critically ill patients with AKI. J Am Soc Nephrol. 2018;29:1011–1019
pubmed: 29196304
doi: 10.1681/ASN.2017060694
Harvey AK, Burns KEA, McArthur E, et al. Short-and long-term outcomes of sustained low efficiency dialysis vs continuous renal replacement therapy in critically ill patients with acute kidney injury. J Crit Care. 2021;62:76–81
pubmed: 33290929
doi: 10.1016/j.jcrc.2020.11.003
Tolwani AJ, Wheeler TS, Wille KM. Sustained low-efficiency dialysis. Contrib Nephrol. 2007;156:320–324
pubmed: 17464142
doi: 10.1159/000102122
Neyra JA, Tolwani A. CRRT prescription and delivery of dose. Semin Dial. 2021;34:432–439
pubmed: 33909931
doi: 10.1111/sdi.12974
Macedo E, Claure-Del Granado R, Mehta RL. Effluent volume and dialysis dose in CRRT: time for reappraisal. Nat Rev Nephrol. 2011;8(1):57–60
pubmed: 22045240
doi: 10.1038/nrneph.2011.172
Ronco C, Bellomo R. New CRRT systems: impact on dose delivery. Am J Kidney Dis. 1997;30(5 Suppl 4):S15–S19
pubmed: 9372974
doi: 10.1016/S0272-6386(97)90537-0
Warrillow S, Fisher C, Tibballs H, Australasian Management of Acute Liver Failure Investigators (AMALFI), et al. Continuous renal replacement therapy and its impact on hyperammonaemia in acute liver failure. Crit Care Resusc. 2020;22(2):158–165
pubmed: 32389108
Fayad AI, Buamscha DG, Ciapponi A. Intensity of continuous renal replacement therapy for acute kidney injury. Cochrane Database Syst Rev. 2016;10:CD010613
pubmed: 27699760
Cardoso FS, Gottfried M, Tujios S, US Acute Liver Failure Study Group, et al. Continuous renal replacement therapy is associated with reduced serum ammonia levels and mortality in acute liver failure. Hepatology. 2018;67:711–720
pubmed: 28859230
doi: 10.1002/hep.29488
Fisher C, Baldwin I, Fealy N, et al. Ammonia clearance with different continuous renal replacement therapy techniques in patients with liver failure. Blood Purif. 2022;51:840–846
pubmed: 35042216
doi: 10.1159/000521312
Saraiva IE, Ortiz-Soriano VM, Mei X, et al. Continuous renal replacement therapy in critically ill patients with acute on chronic liver failure and acute kidney injury: a retrospective cohort study. Clin Nephrol. 2020;93:187–194
pubmed: 32101519
doi: 10.5414/CN109983
Schultheis C, Saugel B, Phillip V, et al. Continuous venovenous hemodialysis with regional citrate anticoagulation in patients with liver failure: a prospective observational study. Crit Care. 2012;22(16):R162
doi: 10.1186/cc11485
Patel S, Wendon J. Regional citrate anticoagulation in patients with liver failure—time for a rethink? Crit Care. 2012;17(16):153
doi: 10.1186/cc11492
Zhang W, Bai M, Yu Y, et al. Safety and efficacy of regional citrate anticoagulation for continuous renal replacement therapy in liver failure patients: a systematic review and meta-analysis. Crit Care. 2019;23(1):22
pubmed: 30678706
pmcid: 6345001
doi: 10.1186/s13054-019-2317-9
Staufer K, Roedl K, Kivaranovic D, et al. Renal replacement therapy in critically ill liver cirrhotic patients-outcome and clinical implications. Liver Int. 2017;37:843–850
pubmed: 28211257
doi: 10.1111/liv.13389
Wang PL, Silver SA, Djerboua M, et al. Recovery from dialysis-treated acute kidney injury in patients with cirrhosis: a population-based study. Am J Kidney Dis. 2022;80:55-64.e1
pubmed: 34808296
doi: 10.1053/j.ajkd.2021.09.025
Del Risco-Zevallos J, Andújar AM, Piñeiro G, et al. Management of acute renal replacement therapy in critically ill cirrhotic patients. Clin Kidney J. 2022;28(15):1060–1070
Allegretti AS, Parada XV, Eneanya ND, et al. Prognosis of patients with cirrhosis and AKI who initiate RRT. Clin J Am Soc Nephrol. 2018;13:16–25
pubmed: 29122911
doi: 10.2215/CJN.03610417
Zhang S, Suen SC, Gong CL, et al. Early transplantation maximizes survival in severe acute-on-chronic liver failure: results of a Markov decision process model. JHEP Rep. 2021;23(3): 100367
doi: 10.1016/j.jhepr.2021.100367
Goussous N, Xie W, Zhang T, et al. Acute on chronic liver failure: factors associated with transplantation. Transplant Direct. 2021;7(12):e788
pubmed: 34805490
pmcid: 8601355
doi: 10.1097/TXD.0000000000001245
Artru F, Louvet A, Ruiz I, et al. Liver transplantation in the most severely ill cirrhotic patients: a multicenter study in acute-on-chronic liver failure grade 3. J Hepatol. 2017;67:708–715
pubmed: 28645736
doi: 10.1016/j.jhep.2017.06.009
Belli LS, Duvoux C, Artzner T, et al. Liver transplantation for patients with acute-on-chronic liver failure (ACLF) in Europe: results of the ELITA/EF-CLIF collaborative study (ECLIS). J Hepatol. 2021;75:610–622
pubmed: 33951535
doi: 10.1016/j.jhep.2021.03.030
Choudhury A, Vijayaraghavan R, Maiwall R, APASL ACLF Research Consortium (AARC) for APASL ACLF Working Party, et al. ‘First week’ is the crucial period for deciding living donor liver transplantation in patients with acute-on-chronic liver failure. Hepatol Int. 2021;15:1376–1388
pubmed: 34608586
doi: 10.1007/s12072-021-10206-6
Sundaram V, Jalan R, Wu T, et al. Factors associated with survival of patients with severe acute-on-chronic liver failure before and after liver transplantation. Gastroenterology. 2019;156:1381-1391.e3
pubmed: 30576643
doi: 10.1053/j.gastro.2018.12.007
Sundaram V, Kogachi S, Wong RJ, et al. Effect of the clinical course of acute-on-chronic liver failure prior to liver transplantation on post-transplant survival. J Hepatol. 2020;72:481–488
pubmed: 31669304
doi: 10.1016/j.jhep.2019.10.013
Gustot T, Fernandez J, Garcia E, NONIC Study Investigators of the EASL-CLIF Consortium, et al. Clinical Course of acute-on-chronic liver failure syndrome and effects on prognosis. Hepatology. 2015;62:243–252
pubmed: 25877702
doi: 10.1002/hep.27849
Asrani SK, Saracino G, O’Leary JG, et al. Recipient characteristics and morbidity and mortality after liver transplantation. J Hepatol. 2018;69:43–50
pubmed: 29454069
doi: 10.1016/j.jhep.2018.02.004
Nadim MK, Genyk YS, Tokin C, et al. Impact of the etiology of acute kidney injury on outcomes following liver transplantation: acute tubular necrosis versus hepatorenal syndrome. Liver Transpl. 2012;18:539–548
pubmed: 22250075
doi: 10.1002/lt.23384
Agbim U, Sharma A, Maliakkal B, et al. Outcomes of liver transplant recipients with acute-on-chronic liver failure based on EASL-CLIF Consortium definition: a single-center study. Transplant Direct. 2020;18(6): e544
doi: 10.1097/TXD.0000000000000984
Goosmann L, Buchholz A, Bangert K, et al. Liver transplantation for acute-on-chronic liver failure predicts post-transplant mortality and impaired long-term quality of life. Liver Int. 2021;41:574–584
pubmed: 34542228
doi: 10.1111/liv.14756
Putignano A, Gustot T. New concepts in acute-on-chronic liver failure: Implications for liver transplantation. Liver Transpl. 2017;23:234–243
pubmed: 27750389
doi: 10.1002/lt.24654
Napoleone L, Solé C, Juanola A, et al. Patterns of kidney dysfunction in acute-on-chronic liver failure: relationship with kidney and patients’ outcome. Hepatol Commun. 2022;6:2121–2221
pubmed: 35535681
pmcid: 9315130
doi: 10.1002/hep4.1963